Lineage Cell Therapeutics Files Definitive Proxy Statement

TL;DR

Lineage Cell Therapeutics filed its proxy statement, shareholders vote soon.

AI Summary

Lineage Cell Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on December 9, 2024. This filing is related to the company's annual meeting and provides information to shareholders regarding voting matters. The company, formerly known as BIOTIME INC, is incorporated in California and operates in the biological products sector.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the company's annual meeting, including any proposals to be voted on, and provides information necessary for informed voting decisions.

Risk Assessment

Risk Level: low — A DEF 14A filing is a routine disclosure document for public companies and does not inherently represent a new risk.

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Registrant
• BIOTIME INC (company) — Former company name
• 20241209 (date) — Filing date

FAQ

Key Financial Figures

• $10,000 — ment will be paid fees of approximately $10,000, plus reimbursement of out-of-pocket ex
• $6.0 million — by the SPA and to receive approximately $6.0 million in gross proceeds from the issuance of
• $0.76 — shares at a combined purchase price of $0.76 per common share and accompanying commo
• $24.0 million — s proposal. We received approximately $24.0 million in gross proceeds from sale and issuanc
• $30.0 million — eeds from the Offering to approximately $30.0 million (or approximately $27.4 million, after
• $27.4 m — imately $30.0 million (or approximately $27.4 million, after deducting placement agent
• $36.0 million — xpenses), excluding up to approximately $36.0 million in gross proceeds we may receive in the
• $120,000 — articipant, the amount involves exceeds $120,000, and any of our executive officers, dir
• $0.91 — will have an initial exercise price of $0.91 per common share. The common warrants w

Filing Documents

• nov_24_rdo_sp_mt_proxy_d.htm (DEF 14A) — 215KB
• img148877704_0.jpg (GRAPHIC) — 77KB
• img148877704_1.jpg (GRAPHIC) — 5KB
• img148877704_2.jpg (GRAPHIC) — 1233KB
• img148877704_3.jpg (GRAPHIC) — 147KB
• 0000950170-24-134577.txt ( ) — 2227KB

From the Filing

DEF 14A 1 nov_24_rdo_sp_mt_proxy_d.htm DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Lineage Cell Therapeutics, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 2173 Salk Ave., Suite 200 Carlsbad, CA 92008 (442) 287-8990 www.lineagecell.com NOTICE OF SPECIAL MEETING OF SHAREHOLDERS To Be Held January 27, 2025 To the Shareholders of Lineage Cell Therapeutics, Inc.: A special meeting of shareholders (the “ Meeting ”) of Lineage Cell Therapeutics, Inc. (“ Lineage ,” “ we ,” “ us ,” and “ our ”) will be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on January 27, 2025 at 8:00 a.m. Pacific Time for the following purposes: 1. To approve, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L.P., and our common shares issuable upon exercise of such common warrants. 2. To approve the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposal if there are not sufficient votes to approve such proposal at the time of the Meeting or any adjournment or postponement thereof. The foregoing items of business are more fully described in the accompanying proxy statement, which forms a part of this notice and is incorporated herein by reference. Except for the items of business described above, no other business may be transacted at the Meeting. Our board of directors recommends that you vote “FOR” all the proposals described in the accompanying proxy statement. You are cordially invited to attend the Meeting. The record date for the Meeting is November 29, 2024. Only shareholders of record at the close of business on the record date are entitled to notice of and to vote at the Meeting or any adjournment or postponement thereof. Your vote is important. Whether or not you expect to attend the Meeting, please vote as soon as possible. You may authorize a proxy to vote your shares via the Internet, by telephone, or by signing, dating and returning the proxy card enclosed herewith in the postage-paid envelope provided. For specific voting instructions, please refer to the information provided in the accompanying proxy statement and proxy card. By Order of the Board of Directors, /s/ Brian M. Culley Brian M. Culley Chief Executive Officer and Director Carlsbad, California December 9, 2024 PROXY STATEMENT FOR THE SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 The board of directors (“ Board ”) of Lineage Cell Therapeutics, Inc. (“ Lineage ,” “ we ,” “ us ” and “ our ”) is soliciting proxies for use at a special meeting of shareholders (the “ Meeting ”) to be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on January 27, 2025 at 8:00 a.m. Pacific Time, including any adjournment or postponement thereof. Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Shareholders to be Held on January 27, 2025: The accompanying notice of the Meeting, this Proxy Statement and the form of proxy card are available at www.proxydocs.com/LCTX . QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE SPECIAL MEETING Why am I receiving these materials? We have prepared these proxy materials, including this Proxy Statement and the related proxy card, because our Board is soliciting your proxy to vote at the Meeting. This Proxy Statement summarizes information related to your vote at the Meeting. All shareholders of record at the close of business on November 29, 2024, the record date for the Meeting, and those who hold a valid proxy on their behalf, are cordially invited to attend the Meeting in person. However, you do not need to attend the Meeting to vote your shares. Instead, you may simply submit your proxy via the Internet, by telephone, or by completing, signing and returning the enclosed proxy card. See also, “How do I

View Full Filing

View this DEF 14A filing on SEC EDGAR